Evidence map›Paper›PMID 38630341›Full record

ArticleJournal of computer-aided molecular design2024

From UK-2A to florylpicoxamid: Active learning to identify a mimic of a macrocyclic natural product.

Ann E Cleves, Ajay N Jain, David A Demeter, Zachary A Buchan, Jeremy Wilmot, Erin N Hancock

Abstract read
In one paragraph

Article in Journal of computer-aided molecular design, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Ann E ClevesBioPharmics Division, Optibrium Limited, Cambridge, CB25 9GL, UK. ann@optibrium.com.ORCID 0000-0002-1622-2770
Ajay N JainBioPharmics Division, Optibrium Limited, Cambridge, CB25 9GL, UK.ORCID 0000-0003-4641-8501
David A DemeterCorteva Agriscience, Indianapolis, IN, 46268, USA.
Zachary A BuchanCorteva Agriscience, Indianapolis, IN, 46268, USA.ORCID 0009-0007-7205-9350
Jeremy WilmotCorteva Agriscience, Indianapolis, IN, 46268, USA.
Erin N HancockCorteva Agriscience, Indianapolis, IN, 46268, USA. erin.hancock@corteva.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Scaffold replacement as part of an optimization process that requires maintenance of potency, desirable biodistribution, metabolic stability, and considerations of synthesis at very large scale is a complex challenge. Here, we consider a set of over 1000 time-stamped compounds, beginning with a macrocyclic natural-product lead and ending with a broad-spectrum crop anti-fungal. We demonstrate the application of the QuanSA 3D-QSAR method employing an active learning procedure that combines two types of molecular selection. The first identifies compounds predicted to be most active of those most likely to be well-covered by the model. The second identifies compounds predicted to be most informative based on exhibiting low predicted activity but showing high 3D similarity to a highly active nearest-neighbor training molecule. Beginning with just 100 compounds, using a deterministic and automatic procedure, five rounds of 20-compound selection and model refinement identifies the binding metabolic form of florylpicoxamid. We show how iterative refinement broadens the domain of applicability of the successive models while also enhancing predictive accuracy. We also demonstrate how a simple method requiring very sparse data can be used to generate relevant ideas for synthetic candidates.

Indexed as

Biological ProductsProblem-Based LearningLactonesPyridinesTissue DistributionBiological ProductsflorylpicoxamidLactonesPyridinesUK 2AActive-learningAffinity predictionMacrocyclesQuanSA

Identifiers

PMID38630341
PMCPMC11639229

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.